BMI is B-A-D, a new study suggests. Here's a better way to measure weight
When it comes to measuring weight, BMI is the acronym everyone loves to hate. Health professionals have long used body mass index as a quick screening tool to fast-track certain patients into a 'code red' management plan — people whose weight puts them in danger of future health problems.
The issue is that BMI measures health risk by calculating height and weight. However, muscle and bone weigh more than fat, so BMI measurements can overestimate the danger for people with a muscular build or a larger frame. Conversely, BMI can underestimate health concerns in older adults and anyone who has lost muscle, according to the Harvard T.H. Chan School of Public Health in Boston.
Now, authors of a new study say a different approach to weight measurement may be a more accurate way to predict future health issues. Bioelectrical impedance analysis, or BIA, uses undetectable electric currents to measure not only the percentage of body fat but also lean muscle mass and water weight.
The technology works like this: You stand on metal plates on the machine while holding your hands or thumbs on another metal attachment held away from the body. Once started, the machine sends a weak electrical current through the body. Body fat, muscle and bone all have different electrical conductivity, so the machine uses algorithms to determine lean muscle mass, body fat percentage and water weight.
'We found body-fat percentage to be a stronger predictor of 15-year mortality risk in adults between the ages of 20 and 49 than BMI,' said Arch Mainous III, lead author of the study published Tuesday in the journal Annals of Family Medicine.
When it came to deaths from heart disease, people with high body fat as measured by BIA were 262% times more likely to die than people who had a healthy percentage of body fat, said Mainous, a professor and vice chair of research in community health and family medicine at the University of Florida School of Medicine.
'Now remember, using BMI did not flag any risk at all in this younger population, which isn't one we typically consider to be at high risk for heart disease,' said senior author Dr. Frank Orlando, a clinical associate professor of community health and family medicine at University of Florida Health.
'Think of the interventions we can do to keep them healthy when we know this early. I think it's a game-changer for how we should look at body composition,' Orlando said.
BMI is measured by dividing your weight by the square of your height. (If you are mathematically challenged like I am, the National Institutes of Health has a free calculator.)
In BMI world, a body mass between 18.5 and 24.9 is a healthy weight, between 25 and 29.9 is overweight, between 30 and 34.9 is obese, between 35 and 39.9 is class 2 obesity, and anything greater than 40 is 'severe' or class 3 obesity. People are considered underweight if their BMI is lower than 18.5.
Using BMI to measure health risk works — on a population level. Countless studies have shown that a greater BMI really does correlate with developing chronic diseases of all kinds — cancer, heart disease, type 2 diabetes, kidney and liver disease, and more.
Where BMI fails is at the patient level. Imagine a patient who is 'skinny fat' — thin on the outside but riddled with globs of fat wrapped around major organs on the inside. Your BMI would be fine even though your health was at risk.
'Those people are more likely to have nonalcoholic fatty liver disease, more likely to have elevated glucose, more likely to have elevated blood pressure, and more likely to have inflammation in general,' Mainous said.
All of these health issues can be treated, stopped and in some cases even reversed if caught early enough, he added.
While doctors are aware of the issues with BMI, many prefer it 'because it is cheap and easily put into practice,' Mainous said. 'They'd like to use a more direct measurement such as a DEXA scan, but those cost too much and are not widely available, so everyone falls back to the indirect measure of BMI.'
DEXA stands for dual-energy X-ray absorptiometry and is the gold standard for body mass analysis. Such machines can cost between $45,000 and $80,000, so patients typically travel to a hospital or specialty center to get the scan, Orlando said. The cost to the patient can easily be $400 to $500 per scan, he said.
'However, we found the newer versions of bioelectrical impedance are pretty accurate, giving some valid and reliable results,' Orlando said.
One note — at-home based bioelectrical impedance products are not nearly as accurate, said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver.
'They can be affected a lot by how much body fluid you have, how hydrated you are,' said Freeman, who was not involved with the new research. 'At-home measurements will only give a ballpark — the clinic-based machines are more precise.'
The new study analyzed data on 4,252 men and women who participated in the 1999 to 2004 federal survey called NHANES, or the National Health and Nutrition Examination Survey, a yearly checkup of the nation's health.
Technicians measured each person's body composition, including height, weight and waist circumference. In addition, all participants underwent a clinic-based bioelectrical impedance analysis, which measures the body's resistance to electrical currents.
Researchers then compared that data with the National Death Index through 2019 to see how many people died. After adjusting for age, race and poverty status, the study found a BMI that labeled someone as obese was not associated with a statistically significant higher risk of death from any cause, when compared with those in healthy BMI range.
People with high body fat as measured by bioimpedance analysis, however, were 78% more likely to die from any cause, Mainous said. Measuring waist circumference was also helpful, but not as accurate as body mass.
Add that to the 262% higher chance of dying from heart disease found by the study, and it's a no-brainer for doctors to use bioelectrical impedance analysis on patients, Orlando said.
'Let's face it, the magnitude of risk this study shows is enormous,' Freeman said. 'It's scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years.'
The study shows how better weight measurements could easily become personalized medicine, Freeman added.
'Imagine you came into your doctor's office,' he said. 'They provided your body fat percentage and an individualized risk assessment. They talked to you about exercise and other lifestyle changes and referred you to a nutritionist.
'They gave you an opportunity to make these changes, and then if needed, helped you out with medication. If the medical profession did this and were able to save many more lives, that would be amazing.'
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
33 minutes ago
- CNN
SCOTUS orders judges to revisit decisions on transgender health plans, birth certificates in wake of blockbuster ruling
The Supreme Court on Monday tossed aside a handful of lower court rulings that sided with transgender Americans, requiring that judges in those cases revisit their decisions in the wake of a blockbuster ruling this month that upheld a ban on gender-affirming care for trans youth. The justices upended rulings that blocked state policies excluding coverage for gender-affirming care in state-sponsored health insurance plans. In a loss for the transgender Americans who sued, those decisions will now be reviewed again. The high court also upended an appeals court ruling that went against Oklahoma in a challenge to the state's effort to ban transgender residents from changing the sex designation on their birth certificates. Lower courts must now review the trio of cases again in light of the Supreme Court's major decision on June 18 that upheld Tennessee's ban on puberty blockers and hormone therapy for trans minors. The 6-3 ruling in US v. Skrmetti steered clear of discussion about other laws involving transgender Americans, but it also did little to protect them in other cases. The court ruled that Tennessee had not discriminated on the basis of sex, which gave the state far more room to regulate medical care. The court also held that the law did not discriminate on the basis of transgender status. This story is breaking and will be updated.
Yahoo
36 minutes ago
- Yahoo
Many People Actually Lose Muscle on a GLP-1. It's Not Too Hard to Avoid—Here's How.
MANY MEN STARTING GLP-1 medications like semaglutide or tirzepatide are trying to lose visceral fat. I've seen this in my work with clients as a dietitian. And targeting visceral fat is a good thing. That's because it's the kind of fat that wraps around your organs and raises your risk for heart disease, diabetes, and other health complications. But here's the thing: Unless you have the right plan, some of the weight you might lose on a GLP-1 might be hard-earned muscle. Recent research suggests that without lifestyle support, such as strength training and adequate protein intake, patients on GLP-1s can lose up to 40 percent of their total body weight, primarily from lean muscle mass rather than fat. Not only could that mean a loss of muscle mass, but a slower metabolism, too. (Not to mention a body composition recovery hill that sucks to climb.) But notice how above I mentioned the right plan? Well, here's that plan—for cutting visceral fat and keeping muscle. Think of your body like a team. GLP-1, a hormone, is your assistant coach that helps everything work together better. It helps you feel full faster, curbs your appetite, and keeps your blood sugar in check. Medications like semaglutide work by mimicking this hormone, lowering your drive to overeat and helping you manage your overall weight more effectively. Except in turning down the hunger signal, a GLP-1 med may also cause you to not consume enough of the right things. Namely protein. "It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Clinics, which operates over 35 weight-loss clinics across the U.S. "Protein is the single most important thing for them to [eat] when taking a GLP-1.' That's because protein is a major building block of muscle. Consume the right amount daily, and you maintain the muscle you have (and, depending on the conditions, grow more). Come up short and muscle loss can happen. The right plan involves a little math, a few adjustments, and some effort. That said, it'll reward you with greater strength and power. How do you know? Find out if that clinic has a registered dietitian on staff or can refer patients to one. Because the goal isn't just to lose weight. It's to keep what matters most while you're doing it. Aim for 1.6 to 2.0 grams of protein per kilogram of body weight per day (which is roughly 0.8 to 1 gram per pound). For a 175-pound guy, that's approximately 140 to 160 grams daily. And don't dump it all into one meal. Distribute your protein evenly, targeting 30 to 40 grams per meal. Leucine—an essential amino acid found in meat, dairy, and whey protein—triggers muscle growth. Prioritize proteins like eggs, fish, Greek yogurt, and beef. For plant-based eaters, be strategic and combine grains and legumes, or consider adding tofu to achieve a complete amino acid profile. Protein shakes, cottage cheese, high-protein yogurts, and foods with added protein and fiber can help bridge the gap, especially when your hunger is low. I love items that have 20-plus grams of protein and 5-plus grams of fiber. Muscle is a "use it or lose it" type of asset. Train with intention at least three times a week. Prioritize resistance training to signal to your body: "Hey, this tissue is still needed.' You Might Also Like The Best Hair Growth Shampoos for Men to Buy Now 25 Vegetables That Are Surprising Sources of Protein
Yahoo
36 minutes ago
- Yahoo
industryGENOME Unveils Groundbreaking Clinical Trial PAO Market Map Report, Powered by AI-Assisted Market Intelligence
TAMPA, Fla., June 30, 2025--(BUSINESS WIRE)--industryGENOME, a cutting-edge analytics firm specializing in granular precision insights, has released its first-ever Clinical Trial Patient Access Organization (PAO) Market Map Report, developed in collaboration with WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, and Crosstree. This report offers an unparalleled bottom-up analysis of the PAO sector, using AI-powered classification models to predict private company revenue and stratify market estimates across geographies, subsidiaries, and specialized capabilities. Transforming Industry Analysis with AI-Assisted Precision Leveraging its proprietary Industry Capabilities Classification System (ICCS®), industryGENOME provides a standardized and globally applicable framework for categorizing businesses. The ICCS® methodology enhances financial analysis, investment decision-making, and strategy development across the life sciences and healthcare industries. The report was developed in close collaboration with WCG, which played a pivotal role in identifying global industry participants to ensure the most comprehensive market representation. Crosstree assisted industryGENOME in industry classification quality assurance and predictive modeling, enhancing the precision of market insights. "This report is the most sophisticated analysis of the clinical trial PAO sector to date," said Shane Senior, Managing Director at Crosstree. "industryGENOME's AI-driven predictive engines achieve 85% classification accuracy, surpassing human classifiers, and ensuring the most precise industry intelligence for investors and market participants. The ability to scale this precision across large data sets is unprecedented." Key Findings from the Clinical Trial PAO Market Map Report Total Market Revenue: $14.95 billion Industry Participants: Over 3,000 global Patient Access Organizations with detailed company profiles for each Industry Stratification: Freestanding, Mobile, Virtual, Provider Embedded, and Service Embedded Sites Top Industry Players: Velocity, IQVIA, PPD, AES, CenExel Clinical Research, ERG, Javara Advanced Market Mapping: AI-assisted data collection and synthesis for high-fidelity revenue estimates allowing for "sum-of-the-parts" bottom-up market sizing Geo-Stratification Analysis: The United States leads with $10.6 billion in revenue, followed by the UK, Germany, and Australia Why This Report Sets a New Standard industryGENOME's bottom-up methodology, empowered by machine learning and predictive analytics, provides unprecedented insights into the PAO sector. The firm's mapped markets process, which identifies, collects, and analyzes micro-industry data, ensures highly precise revenue estimates, critical for investors, procurement specialists, and drug developers seeking strategic market positioning. Access the Report Today To access the Clinical Trial PAO Market Map Report, visit or contact Jordan Schiding at About industryGENOME industryGENOME is a market intelligence platform for the Health Sciences industry that continuously collects and analyzes millions of data points on pharma services companies, investors, deals, valuations, research, conferences, and news. It produces bottom-up market research reports and company profiles by combining AI with the expertise of industry investment professionals. The platform is distinguished by a proprietary, highly granular taxonomy that categorizes industry participant capabilities through defined relationships. This classification system delivers clean, precise, and actionable insights on the Health Sciences market. Using AI technologies—including natural language processing, machine translation, and supervised machine learning—industryGENOME classifies and curates data. In partnership with Crosstree, the platform trains its classification algorithm for accuracy and precision. Together, they are mapping the Health Sciences market one company at a time to deliver detailed, bottom-up industry segment insights. Learn more at About Crosstree Crosstree is a distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three subsectors of the life sciences and healthcare industries: pharmaceutical services, diagnostics and tools, and digital health. Since 2004, Crosstree has advised on more completed transactions in these collective subsectors than any other investment bank. The firm provides clients a full suite of advisory and capital raising services, including both buy-and sell-side mergers and acquisitions advisory, private capital raising, strategic advisory, and valuations. Crosstree's narrow industry focus provides clients the expertise common of a bulge-bracket investment banking firm to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior access to capital markets. From our offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion. About WCG WCG is at the forefront of accelerating clinical research worldwide, serving as the trusted and preferred partner to biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and site partners. Offering a unique combination of expertise, next-generation data and insights, and tech-enabled solutions, WCG reduces complexity and optimizes study operations and outcomes while maintaining the highest standards of human participant protection. For more than 55 years, WCG has maintained a relentless commitment to efficiency, safety, and impact, empowering clinical trials to deliver life-improving therapies swiftly. For more information, please visit or follow us on LinkedIn or X @WCGClinical. View source version on Contacts industryGENOME and Crosstree Media Contact: Hillary McCutcheonFreshwater Marketing813.992.1470hillary@ WCG Media Contact: Carmin Gade, PhDChief Marketing Officer, WCG484.351.9959cgade@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data